title: Involvement of local cholecystokinin in the tolerance induced by morphine microinjections into the periaqueductal gray of rats.
abstract: The ventrolateral periaqueductal gray (PAG) is a key structure for the development of opioid tolerance. An increased activity of 'anti-opioids' like cholecystokinin (CCK) has been proposed as a possible mechanism for opioid tolerance. The present study evaluates the role of PAG-located CCK in the opioid tolerance induced by repeated microinjections of morphine (MOR) into PAG. Male rats were implanted with chronic guide cannulae aimed at the PAG. Microinjection of MOR (0.5 microg in 0.5 microl) into PAG caused antinociception as quantified with the tail flick and the hot plate tests. When MOR microinjection was repeated twice daily, the antinociceptive effect disappeared within 2 days (tolerance). However, if each MOR microinjection was preceded (within 15 min) by a microinjection of the non-selective CCK receptor antagonist proglumide (PRO), (0.4 microg in 0.5 microl) into the same PAG site, the microinjections of MOR always produced antinociception and did not induce tolerance. If PRO microinjections were suspended, subsequent MOR microinjections induced tolerance. In MOR-tolerant rats, a single PRO microinjection into the same PAG site was enough to restore the antinociceptive effect of MOR. On the other hand, if CCK (1 ng in 0.5 microl) was microinjected into PAG, then MOR microinjection administered 15 min later into the same PAG site did not elicit antinociception. These results show that CCK has anti-opioid activity in PAG and that tolerance to MOR in PAG can be prevented or reversed if CCK receptors are blocked with PRO. Finally, opioid tolerance induced by repeated systemic MOR injections (5mg/kg intraperitoneal ) was reversed by a single microinjection of PRO into PAG. This emphasizes the central importance of PAG in the MOR/CCK interactions that lead to opioid tolerance.
authors.affiliation: Instituto Venezolano de Investigaciones Cienti;ficas (IVIC), Apartado 21827, 1020-A, Caracas, Venezuela. victort@cbb.ivic.ve
authors.forename: Víctor
authors.initials: V
authors.lastname: Tortorici
authors.forename: Lourdes
authors.initials: L
authors.lastname: Nogueira
authors.forename: Rafael
authors.initials: R
authors.lastname: Salas
authors.forename: Horacio
authors.initials: H
authors.lastname: Vanegas
mesh_terms: D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology; D002766:Cholecystokinin / Q000378:metabolism / Q000502:physiology*; D004361:Drug Tolerance / Q000502:physiology*; D008297:Male; D008845:Microinjections / Q000379:methods; D009020:Morphine / Q000008:administration & dosage / Q000494:pharmacology*; D010147:Pain Measurement; D010487:Periaqueductal Gray / Q000033:anatomy & histology / Q000187:drug effects* / Q000502:physiology; D011377:Proglumide / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011930:Reaction Time; D013997:Time Factors
chemical_list: D000701:Analgesics, Opioid; D000897:Anti-Ulcer Agents; D009020:Morphine; D002766:Cholecystokinin; D011377:Proglumide